Because of a possible risk of contracting a rare brain disease that is sometimes fatal, Tysabri is generally recommended for US patients who are not responding to or cannot tolerate an alternative MS therapy.
Biogen Idec seeks regulatory OK’s for wider use of a multiple sclerosis drug
You have reached the limit of 10 free articles in a month
Stay informed with unlimited access to Boston’s trusted news source.
- High-quality journalism from the region’s largest newsroom
- Convenient access across all of your devices
- Today’s Headlines daily newsletter
- Subscriber-only access to exclusive offers, events, contests, eBooks, and more
- Less than 25¢ a week